Mylan's Semglee Launch Marks US Multi-Source Competition To Lantus

Aug 31 2020

• By Jessica Merrill

Listen to this article

Mylan is the first to launch insulin glargine competition in both a vial and pre-filled pen, joining Eli Lilly's Basaglar pen.

Many Hands Holding the Red Word Competition, Isolated — Mylan's Semglee launches as another insulin glargine option • Source: Shutterstock

Mylan N.V. is launching Semglee (insulin glargine) as a follow-on version of Sanofi's long-acting insulin Lantus at a list price that will be the lowest available, according to the company. The wholesale acquisition cost (WAC) of Semglee will be $147.98 for a package of five 3mL pens and $98.65 for a 10mL vial, a price which Mylan says will be the lowest WAC for any long-acting insulin glargine on the market.

The company announced the US launch of Semglee on 31 August, after the product, developed with partner Biocon, Ltd.,...

More from Alimentary/Metabolic

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership
Dec 05 2025
• By Jung Won Shin
The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.
Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena
Dec 05 2025
• By Xu Hu
Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s
Mar 10 2025
• By Andrew McConaghie
GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.